MEA Cardiac Safety Services Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143372
- Pages: 225
-
Format:
Short Description
Middle East and Africa Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029
Market Definition:
Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure.
Market Segmentation:
The cardiac safety services market is categorized into four notable segment which is services, type, phase and end user.
On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services.
On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2 and phase 3. In 2022, phase 1 is expected to dominate the global cardiac safety services market with the increasing new drug development and rising strategic initiatives by major market players.
On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services. In 2022, integrated services is expected to dominate the global cardiac safety services market with the increasing advanced technology and rising healthcare expenditure.
On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations and academic and research institute. In 2022, hospital is expected to dominate the global cardiac safety services market with the increasing number of patients and surgeries.
Market Players
The key market players for Middle East and Africa cardiac safety services market are listed below:
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
IQVIA
Medpace
Ncardia
Certara
Eurofins Scientific
SGS SA
TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET 26
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 28
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 SERVICES LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 MARKET END USER GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
4.1 PORTERS FIVE FORCES 47
4.2 PESTEL ANALYSIS 48
5 EPIDEMIOLOGY 49
5.1 INCIDENCE OF ALL BY GENDER 49
5.2 TREATMENT RATE 50
5.3 MORTALITY RATE 50
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51
6 INDUSTRY INSIGHT 52
6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52
6.2 PATENT ANALYSIS 53
6.3 PATENT FLOW DIAGRAM 54
6.4 KEY PATIENT ENROLLMENT STRATEGIES 54
6.5 PRICING STRATEGY 57
7 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58
8 MARKET OVERVIEW 61
8.1 DRIVERS 63
8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63
8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63
8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
8.1.4 INCREASE IN R&D ACTIVITIES 64
8.2 RESTRAINTS 65
8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65
8.2.2 STRICT REGULATORY 65
8.3 OPPORTUNITIES: 66
8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66
8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67
8.4 CHALLENGES 67
8.4.1 TIME-CONSUMING PROCEDURE 67
8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68
9 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69
9.1 OVERVIEW 70
9.2 ECG/HOLTER MEASUREMENTS 74
9.3 BLOOD PRESSURE MEASUREMENTS 74
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75
9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76
9.4.1.1 1 CONCENTRATIONS 76
9.4.1.2 4 CONCENTRATIONS 76
9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77
9.4.2.1 3 CONCENTRATIONS 77
9.4.2.2 5 CONCENTRATIONS 77
9.4.3 IN VITRO HERG ASSAY 77
9.4.4 OTHERS 77
9.5 CARDIOVASCULAR IMAGING 77
9.6 REAL TIME TELEMETRY MONITORING 78
9.7 CENTRAL OVER-READ OF ECGS 79
9.8 NON-INVASIVE CARDIAC IMAGING 79
9.9 PHYSIOLOGIC STRESS TESTING 80
9.10 THOROUGH QT STUDIES 81
9.11 TQT AND EXPOSURE RESPONSE MODELLING 81
9.12 PLATELET AGGREGATION 82
9.13 OTHERS 83
10 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE 84
10.1 OVERVIEW 85
10.2 PHASE I 88
10.3 PHASE II 88
10.4 PHASE III 89
11 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE 90
11.1 OVERVIEW 91
11.2 INTEGRATED SERVICES 94
11.3 STANDALONE SERVICES 95
12 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER 96
12.1 OVERVIEW 97
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100
12.3 CONTRACT RESEARCH ORGANIZATIONS 100
12.4 ACADEMIC AND RESEARCH INSTITUTE 101
13 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY REGION 102
13.1 MIDDLE EAST AND AFRICA 103
13.1.1 SOUTH AFRICA 111
13.1.2 SAUDI ARABIA 114
13.1.3 U.A.E. 117
13.1.4 ISRAEL 120
13.1.5 EGYPT 123
13.1.6 REST OF MIDDLE EAST AND AFRICA 126
14 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 127
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 127
15 COMPANY PROFILE 128
15.1 EUROFINS SCIENTIFIC 128
15.1.1 COMPANY SNAPSHOT 128
15.1.2 REVENUE ANALYSIS 129
15.1.3 COMPANY SHARE ANALYSIS 129
15.1.4 PRODUCT PORTFOLIO 129
15.1.5 RECENT DEVELOPMENTS 130
15.1.5.1 AGREEMENTS 130
15.1.5.2 ACQUISITION 130
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 131
15.2.1 COMPANY SNAPSHOT 131
15.2.2 REVENUE ANALYSIS 131
15.2.3 COMPANY SHARE ANALYSIS 132
15.2.4 PRODUCT PORTFOLIO 132
15.2.5 RECENT DEVELOPMENT 132
15.2.5.1 INVESTMENT 132
15.3 KONINKLIJKE PHILIPS N.V. 133
15.3.1 COMPANY SNAPSHOT 133
15.3.2 REVENUE ANALYSIS 133
15.3.3 COMPANY SHARE ANALYSIS 134
15.3.4 PRODUCT PORTFOLIO 134
15.3.5 RECENT DEVELOPMENT 134
15.3.5.1 ACQUISITION 134
15.4 IQVIA 135
15.4.1 COMPANY SNAPSHOT 135
15.4.2 REVENUE ANALYSIS 135
15.4.3 COMPANY SHARE ANALYSIS 136
15.4.4 PRODUCT PORTFOLIO 136
15.4.5 RECENT DEVELOPMENTS 136
15.4.5.1 ACQUISITION 136
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 137
15.5.1 COMPANY SNAPSHOT 137
15.5.2 REVENUE ANALYSIS 137
15.5.3 COMPANY SHARE ANALYSIS 138
15.5.4 PRODUCT PORTFOLIO 138
15.5.5 RECENT DEVELOPMENTS 138
15.5.5.1 NEW LABORATORY 138
15.5.5.2 ACQUISITION 138
15.6 BANOOK 139
15.6.1 COMPANY SNAPSHOT 139
15.6.2 PRODUCT PORTFOLIO 139
15.6.3 RECENT DEVELOPMENT 139
15.6.3.1 AGREEMENT 139
15.7 BIOTRIAL 140
15.7.1 COMPANY SNAPSHOT 140
15.7.2 PRODUCT PORTFOLIO 140
15.7.3 RECENT DEVELOPMENT 140
15.7.3.1 NEW CENTER OPENING 140
15.8 CELERION 141
15.8.1 COMPANY SNAPSHOT 141
15.8.2 PRODUCT PORTFOLIO 141
15.8.3 RECENT DEVELOPMENT 141
15.8.3.1 NEW CENTER OPENING 141
15.9 CERTARA 142
15.9.1 COMPANY SNAPSHOT 142
15.9.2 REVENUE ANALYSIS 142
15.9.3 PRODUCT PORTFOLIO 143
15.9.4 RECENT DEVELOPMENTS 143
15.9.4.1 CONTRACT 143
15.9.4.2 ACQUISITION 143
15.10 CLARIO 144
15.10.1 COMPANY SNAPSHOT 144
15.10.2 PRODUCT PORTFOLIO 144
15.10.3 RECENT DEVELOPMENT 144
15.10.3.1 PRODUCT EXPANSION 144
15.11 MEDPACE 145
15.11.1 COMPANY SNAPSHOT 145
15.11.2 REVENUE ANALYSIS 145
15.11.3 PRODUCT PORTFOLIO 146
15.11.4 RECENT DEVELOPMENTS 146
15.11.4.1 ACQUISITION 146
15.12 NCARDIA 147
15.12.1 COMPANY SNAPSHOT 147
15.12.2 PRODUCT PORTFOLIO 147
15.12.3 RECENT DEVELOPMENT 147
15.12.3.1 PARTNERSHIP 147
15.13 NEXEL CO., LTD 148
15.13.1 COMPANY SNAPSHOT 148
15.13.2 PRODUCT PORTFOLIO 148
15.13.3 RECENT DEVELOPMENTS 148
15.13.3.1 JOINT VENTURE 148
15.13.3.2 PARTNERSHIP 149
15.14 PHYSIOSTIM 150
15.14.1 COMPANY SNAPSHOT 150
15.14.2 PRODUCT PORTFOLIO 150
15.14.3 RECENT DEVELOPMENT 150
15.14.3.1 PARTNERSHIP 150
15.15 RICHMOND PHARMACOLOGY 151
15.15.1 COMPANY SNAPSHOT 151
15.15.2 PRODUCT PORTFOLIO 151
15.15.3 RECENT DEVELOPMENT 151
15.15.3.1 EVENT 151
15.16 SGS SA 152
15.16.1 COMPANY SNAPSHOT 152
15.16.2 REVENUE ANALYSIS 152
15.16.3 PRODUCT PORTFOLIO 153
15.16.4 RECENT DEVELOPMENT 153
15.16.4.1 ACQUISITION 153
15.17 SHANGHAI MEDICILON INC. 154
15.17.1 COMPANY SNAPSHOT 154
15.17.2 PRODUCT PORTFOLIO 154
15.17.3 RECENT DEVELOPMENTS 154
15.17.3.1 PARTNERSHIP 154
15.17.3.2 PARTNERSHIP 155
16 QUESTIONNAIRE 156
17 RELATED REPORTS 158
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
